3 Reasons to Buy Eli Lilly Stock

The article argues Eli Lilly still has significant upside, citing rapid growth in anti-obesity drugs, a deep pipeline, and dividend growth of 239% over 10 years. It highlights Zepbound, Mounjaro, and Foundayo as key growth drivers, plus pipeline assets like retatrutide and MORF-057 that could diversify revenue beyond diabetes and obesity. The piece is broadly bullish but is mostly opinion-driven commentary rather than a new catalyst, so market impact should be limited.

Analysis

LLY is transitioning from a single-category obesity winner into a platform asset, and that matters more than near-term prescription momentum. The market is still underestimating how much of the obesity opportunity will be defined by convenience, broader label utility, and physician workflow rather than pure efficacy; oral, dual-indication, and no-restriction administration can drive disproportionate share capture as access broadens. That creates a second-order squeeze on competitors: not just GLP-1 rivals, but also infusion/injectable incumbents across adjacent metabolic and inflammatory franchises that may face slower adoption curves when patients and doctors can simplify treatment.

The bigger medium-term question is not demand, but mix. If obesity/diabetes remains >60% of revenue, the stock is vulnerable to multiple compression whenever growth expectations for the core normalize, even if absolute sales keep rising. The real upside catalyst is pipeline optionality: successful non-obesity launches can re-rate LLY from a “best-in-class obesity compounder” to a diversified pharma platform, which would justify a more durable premium multiple and reduce the market’s sensitivity to any future GLP-1 pricing pressure.

The contrarian view is that the stock’s scarcity premium may already embed too much optimism around a multi-year runway in obesity, while the pipeline still carries binary execution risk. The market may also be underappreciating payor friction once obesity becomes a larger budget line item; that could show up first in step edits, tighter prior auth, and weaker net pricing before it appears in headline unit growth. Over a 6-18 month horizon, the key risk is not a demand cliff but margin reversion if rebate intensity rises faster than volume growth.

Dividend support is a useful floor, but not the main thesis. The yield is too low to attract income capital on its own; the more relevant signal is management’s ability to keep capital allocation disciplined while funding multiple shots on goal. If pipeline execution remains clean, LLY can still compound; if not, the current valuation leaves limited room for disappointment.

Key Decisions for Investors

• Stay long LLY on a 6-12 month horizon, but treat it as a quality compounder rather than a momentum chase; best entry is on 5-8% pullbacks when the market rotates away from GLP-1 leadership.
• Add a call spread to express upside from non-obesity pipeline success: buy LLY 12-18 month 900/1050 call spreads if the stock weakens post-print; risk is defined and catalysts are clinical readouts plus label expansion.
• Pair trade: long LLY / short a basket of lower-quality obesity beneficiaries with less pipeline breadth and weaker oral convenience positioning; thesis is share consolidation and multiple dispersion over the next 2-4 quarters.
• For event risk, hedge existing LLY longs with 3-6 month puts around major clinical/regulatory dates; the main downside is not failure of the core franchise but a pipeline miss that narrows the diversification story.
• If seeking cleaner upside asymmetry, wait for evidence that non-obesity assets can move revenue mix by at least a few points over the next 12 months before adding aggressively; otherwise the valuation remains sensitive to any slowdown in obesity net pricing.